NICE to Charge up to $282,000 for New Drug Assessments

The UK’s National Institute of Health and Care Excellence (NICE) plans to start charging pharmaceutical companies new fees for each cost-effectiveness assessment for a new medicine beginning next year. The new fees could be up to $282,000! Find out more here. (Source: Zachary Brennan, RAPS, 10/3/16)

You might also be interested in:

Trump's "Buy American" Executive Order Could Raise Drug Prices 08/06/2020
ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020
Are Healthcare Prices in the U.S. Too High, Too Low, or Both? 08/25/2020
What Are The Recent Top 4 Innovative Consolidations and… 08/26/2020
Key Innovations Coming From The Next Generation of PBM’s 08/12/2020
How HEOR Professionals Can Be Force Multipliers in the Fight… 10/06/2020
BHE Rebrands Itself as Panalgo In Effort To Empower Pharma,… 08/14/2020